Table 2 Clinical characteristics of AEG patients in the SEER and our center set
Clinical features | SEER set | Our center set |
|---|---|---|
Sample size | 1930 | 174 |
Survival time (months, median [IQR]) | 24.00 [13.00, 43.00] | 26.67 [16.93, 45.85] |
Survival status (%) | Â | Â |
Alive | 994 (51.5) | 132 (75.9) |
Dead | 936 (48.5) | 42 (24.1) |
Age (years, median [IQR]) | 63.00 [55.00, 70.00] | 65.50 [60.00, 71.00] |
Sex (%) | Â | Â |
Female | 356 (18.4) | 34 (19.5) |
Male | 1574 (81.6) | 140 (80.5) |
Histologic grade (%) | Â | Â |
Well differentiated | 120 (6.2) | 12 (6.9) |
Moderately differentiated | 728 (37.7) | 68 (39.1) |
Poorly differentiated | 1051 (54.5) | 92 (52.9) |
Undifferentiated | 31 (1.6) | 2 (1.1) |
Tumor size (%) | Â | Â |
≤1 cm | 155 (8.0) | 7 (4.0) |
1-2 cm | 294 (15.2) | 23 (13.2) |
2-3 cm | 356 (18.4) | 35 (20.1) |
3-4 cm | 337 (17.5) | 46 (26.4) |
4-5 cm | 276 (14.3) | 23 (13.2) |
> 5 cm | 512 (26.5) | 40 (23.0) |
pStage (%) | Â | Â |
I | 373 (19.3) | 43 (24.7) |
II | 472 (24.5) | 63 (36.2) |
III | 986 (51.1) | 63 (36.2) |
IV | 99 (5.1) | 5 (2.9) |
pT stage (%) | Â | Â |
T1 | 389 (20.2) | 25 (14.4) |
T2 | 270 (14.0) | 31 (17.8) |
T3 | 1136 (58.9) | 79 (45.4) |
T4 | 135 (7.0) | 39 (22.4) |
pN stage (%) | Â | Â |
N0 | 716 (37.1) | 70 (40.2) |
N1 | 632 (32.7) | 35 (20.1) |
N2 | 344 (17.8) | 34 (19.5) |
N3 | 238 (12.3) | 35 (20.1) |
pM stage (%) | Â | Â |
M0 | 1831 (94.9) | 169 (97.1) |
M1 | 99 (5.1) | 5 (2.9) |
Chemotherapy status (%) | Â | Â |
No/Unknown | 542 (28.1) | 40 (23.0) |
Yes | 1388 (71.9) | 134 (77.0) |
Positive LNs number (median [IQR]) | 1.00 [0.00, 3.00] | 1.00 [0.00, 5.00] |
Examined LNs number (median [IQR]) | 16.00 [10.00, 23.00] | 30.00 [22.00, 38.00] |
Ratio of metastasis LNs (median [IQR]) | 0.03 [0.00, 0.20] | 0.05 [0.00, 0.19] |